Sanofi and Genzyme recover domain at WIPO
16-11-2016
Sanofi and Boehringer Ingelheim to swap businesses
28-07-2016
nitpicker / Shutterstock.com
Sanofi will buy British immunotherapy firm Kymab for up to $1.45 billion, as it seeks to expand in the rapidly growing immunotherapy field.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Sanofi, Kymab, immunotherapy, Principia Biopharma, Kiadis, KY1005
